
Product ID: SQSG35B2010
Report ID: SQSG35B2010 | Region: Global | Published Date: October, 2022 | Pages: 260 | Tables: 96 | Figures: 76
"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "
- Mr. Ali Zali, Commercial Director, ICIIC Iran.
Our industry expert will work with you to provide you with customized data in a short amount of time.
SPEAK TO AN ANALYSTGet lifetime access to our insights
Basic Plan $5,000 Team Plan $10,000 SUBSCRIBE NOWCentral Nervous System Treatment Market size was valued at USD 120.64 billion in 2021 and is poised to grow from USD 128.29 billion in 2022 to USD 209.2 billion by 2030, growing at a CAGR of 6.3% in the forecast period (2023-2030).
Mergers, acquisitions, and partnerships are among the important market trends that are present. Major players in the market who are developing novel therapeutics for the treatment of disorders of the central nervous system have agreements with rival firms for distribution and research and development. For instance, Biogen and Sangamo Therapeutics reached an agreement to develop novel gene therapy medications for a range of neurological illnesses. The prospects of the CNS therapeutics market would be greatly improved by strategic actions implemented by leading businesses. 'Pfizer Inc.', 'Novartis International AG', 'Johnson & Johnson', 'GlaxoSmithKline plc', 'Merck & Co., Inc.', 'AbbVie Inc.', 'Sanofi S.A.', 'Eli Lilly and Company', 'AstraZeneca plc', 'Biogen Inc.', 'Teva Pharmaceutical Industries Ltd.', 'UCB S.A.', 'Boehringer Ingelheim International GmbH', 'Bristol-Myers Squibb Company', 'Ipsen S.A.', 'Lundbeck A/S', 'Otsuka Holdings Co., Ltd.', 'Sunovion Pharmaceuticals Inc.', 'Takeda Pharmaceutical Company Limited', 'Vertex Pharmaceuticals Incorporated'
The frequency and incidence of neurological illnesses, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease, among others, are rapidly rising globally. In the upcoming years, the market's growth is expected to be significantly impacted by this increase. On the other side, countries with an increasing geriatric population are also experiencing an upsurge in the prevalence of Alzheimer's disease. For instance, the Alzheimer's Association estimates that more than five million people worldwide already suffer from Alzheimer's disease, and that figure is expected to increase to 14 million by the year 2050.
Improvements in Diagnosis and Therapeutics: The development of the therapeutics market for the central nervous system is being fuelled by improvements in diagnostics, therapies, and drug discovery approaches.
By holding the greatest revenue share of 49.3%, North America dominated the market for CNS therapeutics. The presence of large corporations and efforts made by major medical organizations to create novel medicines for various central nervous system ailments are the factors anticipated to enhance the total market share.
Product ID: SQSG35B2010